Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 20 clinical trials
Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor Copanlisib Given in Combination With the Immunotherapeutic Agents Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma

Patients with relapsed or refractory follicular or marginal zone lymphoma who have received at least one prior line of therapy will receive Copanlisib IV: day 1, 8, 15 every 28 days Nivolumab IV: Cycle 1 days 1 and 15; then day 1 only Rituximab IV: Cycle 1 days 1, 8, …

  • 0 views
  • 06 Nov, 2021
  • 4 locations
Effect of Vegan Diet and Lifestyle Changes on Indolent Lymphoma During Controlled Waiting Period

The aim of the present trial is to evaluate the effect of lifestyle changes on the natural history of indolent lymphomas, during the period of watchful waiting. The intervention program is

  • 0 views
  • 20 Jul, 2021
  • 1 location
Efficacy of Palliative Low-Dose Involved-Field Radiation Therapy for Recurrent Advanced Follicular Lymphoma

Many trials that patients with advanced or recurrent indolent lymphoma managed with very low-dose (4Gy) limited-field RT (LD-IFRT) have shown that high response rates and durable remission can

  • 7 views
  • 21 Jan, 2021
  • 1 location
Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients

A randomized phase III multicenter trial assessing efficacy and toxicity of a combination of Rituximab and Lenalidomide (R2) vs Rituximab alone as maintenance after chemoimmunotherapy with Rituximab-chemotherapy (R-CHT) for relapsed/refractory FL patients not eligible for autologous transplantation (ASCT)

platelet count
neutrophil count
rituximab
bendamustine
tumor burden
  • 47 views
  • 06 Sep, 2021
  • 37 locations
IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma.

Follicular lymphoma (FL) and marginal zone lymphoma (MZL) are the most common inert non Hodgkin's lymphoma (iNHL). The standard first-line treatment of advanced FL / MZL is based on rituximab. Whether combined with chemotherapy or not, iNHL can induce lasting remission, but most of it is usually incurable. Therefore, early …

  • 0 views
  • 20 Oct, 2021
Safety Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects

, including multiple myeloma (MM), mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), indolent lymphoma, adult T-cell leukemia-lymphoma (ATL), or chronic lymphocytic

calcium
lymphoid leukemia
cancer
chronic lymphocytic leukemia
multiple myeloma
  • 0 views
  • 16 Jun, 2021
  • 3 locations
Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma

, 41 with follicular lymphoma (FL), 20 with Mantle Cell Lymphoma (MCL) and 20 with other indolent lymphomas, and 20 patients with Hodgkin lymphoma (HL)). FL patients with EZH2 mutant (gain of function

anti-cd20 monoclonal antibody
high grade lymphoma
renal function
high grade b-cell lymphoma
marginal zone lymphoma
  • 0 views
  • 27 Jun, 2021
  • 22 locations
Efficacy of Carfilzomib in Combination With Ibrutinib in Waldenstr m's Macroglobulinemia

In Waldenstrm macroglobulinemia (WM) chemotherapy induces only low CR/VGPR (Complete Remission/ Very Good Partial Response) rates and responses of short duration compared to other indolent

cold agglutinin
anemia
monoclonal protein
dexamethasone
platelet count
  • 0 views
  • 17 Sep, 2021
  • 11 locations
Study of STRO-001 an Anti-CD74 Antibody Drug Conjugate in Patients With Advanced B-Cell Malignancies

First-in-human Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-001 given intravenously every 3 weeks.

bone marrow procedure
cancer
measurable disease
  • 178 views
  • 26 Jan, 2021
  • 21 locations
NKX019 Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK) in Adults With B-cell Cancers

This is a single arm, open-label, multi-center, Phase 1 study to determine the safety and tolerability of an experimental therapy called NKX019 (allogeneic CAR NK cells targeting CD19) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL) or B cell acute lymphoblastic leukemia (B-ALL)

indolent lymphoma
monoclonal protein
b-cell small lymphocytic lymphoma
tyrosine
platelet count
  • 0 views
  • 26 Nov, 2021
  • 5 locations